ImmuPharma plc (LON:IMM – Get Free Report) was up 191.7% on Thursday . The company traded as high as GBX 3.80 ($0.05) and last traded at GBX 3.50 ($0.04). Approximately 104,299,430 shares traded hands during mid-day trading, an increase of 470% from the average daily volume of 18,292,627 shares. The stock had previously closed at GBX 1.20 ($0.01).
ImmuPharma Trading Up 4.9 %
The firm has a market capitalization of £15.30 million, a P/E ratio of -367.30 and a beta of 1.53. The company has a 50-day moving average of GBX 1.40 and a 200-day moving average of GBX 1.65.
About ImmuPharma
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Read More
- Five stocks we like better than ImmuPharma
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Transportation Stocks Investing
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- Overbought Stocks Explained: Should You Trade Them?
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
